{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:13:03Z","timestamp":1789913583274,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SP50AI074178"],"award-info":[{"award-number":["SP50AI074178"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["Institute Pasteur International Network"],"award-info":[{"award-number":["Institute Pasteur International Network"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1458-6","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T02:06:17Z","timestamp":1458785177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Protein biomarkers discriminate Leishmania major-infected and non-infected individuals in areas endemic for cutaneous leishmaniasis"],"prefix":"10.1186","volume":"16","author":[{"given":"Wafa","family":"Kammoun-Rebai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikbel","family":"Naouar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Libri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hechmi","family":"Louzir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Meddeb-Garnaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"1458_CR1","unstructured":"WHO. Control of the leishmaniasis Report 2010"},{"key":"1458_CR2","unstructured":"WHO | Leishmaniasis."},{"key":"1458_CR3","doi-asserted-by":"crossref","unstructured":"WHO EMRO | Cutaneous leishmaniasis caused by Leishmania major in Morocco: still a topical question | Volume 19, issue 5 | EMHJ volume 19, 2013.","DOI":"10.26719\/2013.19.5.495"},{"key":"1458_CR4","doi-asserted-by":"crossref","unstructured":"Ben Salah A, Louzir H, Chlif S, Mokni M, Zaatour A, Raouene M, Ismail R Ben, Dellagi K. The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. J Infect Dis. 2005;192:1981\u20137.","DOI":"10.1086\/498042"},{"key":"1458_CR5","doi-asserted-by":"crossref","unstructured":"Sassi a., Louzir H, Salah a. Ben, Mokni M, Osman a. Ben, Dellagi K: Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin Exp Immunol 1999, 116:127\u2013132.","DOI":"10.1046\/j.1365-2249.1999.00844.x"},{"key":"1458_CR6","doi-asserted-by":"crossref","unstructured":"Kedzierski L, Evans KJ. Immune responses during cutaneous and visceral leishmaniasis. Parasitology. 2014;1\u201319.","DOI":"10.1017\/S003118201400095X"},{"key":"1458_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/expr.1996.4139","volume":"85","author":"EL Racoosin","year":"1997","unstructured":"Racoosin EL, Beverley SM. Leishmania major: promastigotes induce expression of a subset of chemokine genes in murine macrophages. Exp Parasitol. 1997;85:283\u201395.","journal-title":"Exp Parasitol"},{"key":"1458_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.imbio.2007.12.005","volume":"213","author":"J Liese","year":"2008","unstructured":"Liese J, Schleicher U, Bogdan C. The innate immune response against Leishmania parasites. Immunobiology. 2008;213:377\u201387.","journal-title":"Immunobiology"},{"key":"1458_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00062752-200001000-00006","volume":"7","author":"MM Kane","year":"2000","unstructured":"Kane MM, Mosser DM. Leishmania parasites and their ploys to disrupt macrophage activation. Curr Opin Hematol. 2000;7:26\u201331.","journal-title":"Curr Opin Hematol"},{"key":"1458_CR10","doi-asserted-by":"crossref","unstructured":"Von Stebut E, Ehrchen JM, Belkaid Y, Kostka SL, Molle K, Knop J, Sunderkotter C, Udey MC. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB\/c mice. J Exp Med. 2003;198:191\u20139.","DOI":"10.1084\/jem.20030159"},{"key":"1458_CR11","first-page":"556","volume":"71","author":"FY Liew","year":"1990","unstructured":"Liew FY, Li Y, Millott S. Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology. 1990;71:556\u20139.","journal-title":"Immunology"},{"key":"1458_CR12","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.4049\/jimmunol.162.12.7302","volume":"162","author":"M Mohrs","year":"1999","unstructured":"Mohrs M, Ledermann B, K\u00f6hler G, Dorfm\u00fcller A, Gessner A, Brombacher F. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol. 1999;162:7302\u20138.","journal-title":"J Immunol"},{"key":"1458_CR13","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.4049\/jimmunol.162.10.6132","volume":"162","author":"N Noben-Trauth","year":"1999","unstructured":"Noben-Trauth N, Paul WE, Sacks DL. IL-4- and IL-4 receptor-deficient BALB\/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol. 1999;162:6132\u201340.","journal-title":"J Immunol"},{"key":"1458_CR14","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.4049\/jimmunol.164.3.1458","volume":"164","author":"DJ Matthews","year":"2000","unstructured":"Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol. 2000;164:1458\u201362.","journal-title":"J Immunol"},{"key":"1458_CR15","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1128\/IAI.71.8.4804-4807.2003","volume":"71","author":"S St\u00e4ger","year":"2003","unstructured":"St\u00e4ger S, Alexander J, Carter KC, Brombacher F, Kaye PM. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun. 2003;71:4804\u20137.","journal-title":"Infect Immun"},{"key":"1458_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-3024.1999.00224.x","volume":"21","author":"R Chatelain","year":"1999","unstructured":"Chatelain R, Mauze S, Coffman RL. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 1999;21:211\u20138.","journal-title":"Parasite Immunol"},{"key":"1458_CR17","doi-asserted-by":"crossref","unstructured":"Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O\u2019Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991;146:3444\u201351.","DOI":"10.4049\/jimmunol.146.10.3444"},{"key":"1458_CR18","doi-asserted-by":"publisher","first-page":"A49","DOI":"10.1016\/S0167-5699(05)80015-5","volume":"12","author":"TR Mosmann","year":"1991","unstructured":"Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today. 1991;12:A49\u201353.","journal-title":"Immunol Today"},{"key":"1458_CR19","unstructured":"Measurement of Delayed Skin-Test Responses \u2014 NEJM"},{"key":"1458_CR20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4269\/ajtmh.1991.44.260","volume":"44","author":"KA Weigle","year":"1991","unstructured":"Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am J Trop Med Hyg. 1991;44:260\u201371.","journal-title":"Am J Trop Med Hyg"},{"key":"1458_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0035-9203(75)90012-7","volume":"69","author":"S Pampiglione","year":"1975","unstructured":"Pampiglione S, Manson-Bahr PE, La Placa M, Borgatti MA, Musumeci S. Studies in Mediterranean leishmaniasis. 3. The leishmanin skin test in kala-azar. Trans R Soc Trop Med Hyg. 1975;69:60\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1458_CR22","doi-asserted-by":"crossref","unstructured":"Acedo S\u00e1nchez C, Mart\u00edn S\u00e1nchez J, V\u00e9lez Bernal ID, Sanch\u00eds Mar\u00edn MC, Louassini M, Maldonado JA, Morillas M\u00e1rquez F. Leishmaniasis eco-epidemiology in the Alpujarra region (Granada Province, southern Spain). Int J Parasitol. 1996;26:303\u201310.","DOI":"10.1016\/0020-7519(95)00124-7"},{"key":"1458_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/infdis\/154.4.639","volume":"154","author":"R Badar\u00f3","year":"1986","unstructured":"Badar\u00f3 R, Jones TC, Loren\u00e7o R, Cerf BJ, Sampaio D, Carvalho EM, Rocha H, Teixeira R, Johnson WD. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis. 1986;154:639\u201349.","journal-title":"J Infect Dis"},{"key":"1458_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/expr.2001.4656","volume":"99","author":"GF Sp\u00e4th","year":"2001","unstructured":"Sp\u00e4th GF, Beverley SM. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol. 2001;99:97\u2013103.","journal-title":"Exp Parasitol"},{"key":"1458_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.exppara.2007.06.012","volume":"118","author":"C Yao","year":"2008","unstructured":"Yao C, Chen Y, Sudan B, Donelson JE, Wilson ME. Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model. Exp Parasitol. 2008;118:129\u201333.","journal-title":"Exp Parasitol"},{"key":"1458_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri933","volume":"2","author":"D Sacks","year":"2002","unstructured":"Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2:845\u201358.","journal-title":"Nat Rev Immunol"},{"key":"1458_CR27","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1128\/IAI.68.4.1760-1764.2000","volume":"68","author":"S Ajdary","year":"2000","unstructured":"Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun. 2000;68:1760\u20134.","journal-title":"Infect Immun"},{"key":"1458_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1046\/j.1365-3083.1999.00554.x","volume":"49","author":"K Kemp","year":"1999","unstructured":"Kemp K, Theander TG, Hviid L, Garfar A, Kharazmi A, Kemp M. Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol. 1999;49:655\u20139.","journal-title":"Scand J Immunol"},{"key":"1458_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.imlet.2013.12.022","volume":"161","author":"R Hurdayal","year":"2014","unstructured":"Hurdayal R, Brombacher F. The role of IL-4 and IL-13 in cutaneous Leishmaniasis. Immunol Lett. 2014;161:179\u201383.","journal-title":"Immunol Lett"},{"key":"1458_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1086\/319249","volume":"183","author":"E Bourreau","year":"2001","unstructured":"Bourreau E, Pr\u00e9vot G, Pradinaud R, Launois P. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis. 2001;183:953\u20139.","journal-title":"J Infect Dis"},{"key":"1458_CR31","doi-asserted-by":"crossref","unstructured":"Nateghi Rostami M, Keshavarz Valian H, Eskandari SE, Miramin Mohammadi A, Shahrestani ST, Sarraf-Nejad A, Khamesipour A. Differential in vitro CD4+\/CD8+ T-cell response to live vs. killed Leishmania major. Parasite Immunol. 2010;32:101\u201310.","DOI":"10.1111\/j.1365-3024.2009.01164.x"},{"key":"1458_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.micinf.2008.07.038","volume":"10","author":"J Alexander","year":"2008","unstructured":"Alexander J, McFarlane E. Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent? Microbes Infect. 2008;10:953\u20139.","journal-title":"Microbes Infect"},{"key":"1458_CR33","doi-asserted-by":"crossref","unstructured":"Gurung P, Karki R, Vogel P, Watanabe M, Bix M, Lamkanfi M, Kanneganti T-D. An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis. J Clin Invest. 2015;125:1329\u201338.","DOI":"10.1172\/JCI79526"},{"key":"1458_CR34","doi-asserted-by":"crossref","unstructured":"Sousa LMA, Carneiro MBH, Dos Santos LM, Natale CC, Resende ME, Mosser DM, Vieira LQ. IL-18 contributes to susceptibility to Leishmania amazonensis infection by macrophage-independent mechanisms. Cytokine. 2015;74:327\u201330.","DOI":"10.1016\/j.cyto.2015.01.021"},{"key":"1458_CR35","doi-asserted-by":"crossref","unstructured":"Li Y, Ishii K, Hisaeda H, Hamano S, Zhang M, Nakanishi K, Yoshimoto T, Hemmi H, Takeda K, Akira S, Iwakura Y, Himeno K. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB\/c mice: is the effect mediated by the CpG signaling TLR9? Gene Ther. 2004;11:941\u20138.","DOI":"10.1038\/sj.gt.3302240"},{"key":"1458_CR36","doi-asserted-by":"crossref","unstructured":"Lima-Junior DS, Costa DL, Carregaro V, Cunha LD, Silva ALN, Mineo TWP, Gutierrez FRS, Bellio M, Bortoluci KR, Flavell RA, Bozza MT, Silva JS, Zamboni DS. Inflammasome-derived IL-1\u03b2 production induces nitric oxide-mediated resistance to Leishmania. Nat Med. 2013;19:909\u201315.","DOI":"10.1038\/nm.3221"},{"key":"1458_CR37","doi-asserted-by":"crossref","unstructured":"Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, Barral A, Almeida RP, Mayrink W, Locksley R, Gollob KJ. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun. 2001;69:3232\u20139.","DOI":"10.1128\/IAI.69.5.3232-3239.2001"},{"key":"1458_CR38","doi-asserted-by":"crossref","unstructured":"Faria DR, Gollob KJ, Barbosa J, Schriefer A, Machado PRL, Lessa H, Carvalho LP, Romano-Silva MA, de Jesus AR, Carvalho EM, Dutra WO. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun. 2005;73:7853\u20139.","DOI":"10.1128\/IAI.73.12.7853-7859.2005"},{"key":"1458_CR39","doi-asserted-by":"crossref","unstructured":"Boaventura VS, Santos CS, Cardoso CR, De Andrade J, Dos Santos WLC, Clar\u00eancio J, Silva JS, Borges VM, Barral-Netto M, Brodskyn CI, Barral A. Human mucosal leishmaniasis: Neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol. 2010;40:2830\u20136.","DOI":"10.1002\/eji.200940115"},{"key":"1458_CR40","doi-asserted-by":"crossref","unstructured":"Bacellar O, Faria D, Nascimento M, Cardoso TM, Gollob KJ, Dutra WO, Scott P, Carvalho EM. Interleukin 17 production among patients with American cutaneous leishmaniasis. J Infect Dis. 2009;200:75\u20138.","DOI":"10.1086\/599380"},{"key":"1458_CR41","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.4049\/jimmunol.0713598","volume":"182","author":"S Lopez Kostka","year":"2009","unstructured":"Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol. 2009;182:3039\u201346.","journal-title":"J Immunol"},{"key":"1458_CR42","unstructured":"Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S, Carvalho LP, Goldschmidt M, Carvalho EM, Scott P. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013;9, e1003243."},{"key":"1458_CR43","doi-asserted-by":"crossref","unstructured":"Nascimento MSL, Carregaro V, Lima-J\u00fanior DS, Costa DL, Ryffel B, Duthie MS, de Jesus A, de Almeida RP, da Silva JS. Interleukin 17A acts synergistically with interferon \u03b3 to promote protection against Leishmania infantum infection. J Infect Dis. 2015;211:1015\u201326.","DOI":"10.1093\/infdis\/jiu531"},{"key":"1458_CR44","doi-asserted-by":"crossref","unstructured":"Pitta MGR, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, Argiro L, el Kheir M, Bucheton B, Mary C, El-Safi SH, Dessein A. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest. 2009;119:2379\u201387.","DOI":"10.1172\/JCI38813"},{"key":"1458_CR45","doi-asserted-by":"crossref","unstructured":"Almeida RP, Brito J, Machado PL, DE Jesus AR, Schriefer A, Guimar\u00e3es LH, Carvalho EM. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg. 2005;73:79\u201381.","DOI":"10.4269\/ajtmh.2005.73.79"},{"key":"1458_CR46","unstructured":"Schnorr D, Muniz AC, Passos S, Guimaraes LH, Lago EL, Bacellar O, Glesby MJ, Carvalho EM. IFN-\u03b3 Production to Leishmania Antigen Supplements the Leishmania Skin Test in Identifying Exposure to L. braziliensis Infection. PLoS Negl Trop Dis. 2012;6, e1947."},{"key":"1458_CR47","doi-asserted-by":"publisher","first-page":"ra104","DOI":"10.1126\/scisignal.aab0808","volume":"8","author":"KB Arnold","year":"2015","unstructured":"Arnold KB, Szeto GL, Alter G, Irvine DJ, Lauffenburger DA. CD4+ T cell-dependent and CD4+ T cell-independent cytokine-chemokine network changes in the immune responses of HIV-infected individuals. Sci Signal. 2015;8:ra104.","journal-title":"Sci Signal"},{"key":"1458_CR48","doi-asserted-by":"crossref","unstructured":"Duffy D, Mamdouh R, Laird M, Soneson C, Le Fouler L, El-Daly M, Casrouge A, Decalf J, Abbas A, Eldin NS, Fontes M, Abdel-Hamid M, Mohamed MK, Rafik M, Fontanet A, Albert ML. The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis. Hepatology. 2014;59:1273\u201382.","DOI":"10.1002\/hep.26901"},{"key":"1458_CR49","doi-asserted-by":"crossref","unstructured":"Duffy D, Rouilly V, Libri V, Hasan M, Beitz B, David M, Urrutia A, Bisiaux A, Labrie ST, Dubois A, Boneca IG, Delval C, Thomas S, Rogge L, Schmolz M, Quintana-Murci L, Albert ML. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity. 2014;40:436\u201350.","DOI":"10.1016\/j.immuni.2014.03.002"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-016-1458-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1458-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:05:20Z","timestamp":1692266720000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1458-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1458-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]},"assertion":[{"value":"19 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"138"}}